



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Increased risk of *Staphylococcus aureus* bacteremia in hemodialysis-A nationwide study

Chaudry, Mavish S; Gislason, Gunnar H; Kamper, Anne-Lise; Rix, Marianne; Larsen, Anders R; Petersen, Andreas; Andersen, Paal S; Skov, Robert L; Fosbøl, Emil L; Westh, Henrik; Schønheyder, Henrik C; Benfield, Thomas L; Fowler, Vance G; Torp-Pedersen, Christian; Bruun, Niels E

Published in:
Hemodialysis International

DOI (link to publication from Publisher):
[10.1111/hdi.12728](https://doi.org/10.1111/hdi.12728)

Publication date:
2019

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Chaudry, M. S., Gislason, G. H., Kamper, A-L., Rix, M., Larsen, A. R., Petersen, A., Andersen, P. S., Skov, R. L., Fosbøl, E. L., Westh, H., Schønheyder, H. C., Benfield, T. L., Fowler, V. G., Torp-Pedersen, C., & Bruun, N. E. (2019). Increased risk of *Staphylococcus aureus* bacteremia in hemodialysis-A nationwide study. *Hemodialysis International*, 23(2), 230-238. <https://doi.org/10.1111/hdi.12728>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Increased risk of *Staphylococcus aureus* bacteremia in hemodialysis – a nationwide study

Hemodialysis vascular access

Mavish S. Chaudry MD¹, Gunnar H. Gislason MD, PhD^{1,2}, Anne-Lise Kamper MD, DMSc³, Marianne Rix MD, PhD³, Anders R. Larsen M.Sc. PhD⁴, Andreas Petersen⁴, Paal S. Andersen M.Sc^{4,5}, PhD, Robert L. Skov MD⁴, Emil L. Fosbøl MD, PhD⁶, Henrik Westh MD, DMSc⁷, Henrik C. Schönheyder MD, DMSc^{8,9}, Thomas L. Benfield MD, DMSc⁷, Vance G. Fowler, Jr, MD, MHS¹⁰, Christian Torp-Pedersen MD, DMSc¹¹, Niels E. Bruun MD, DMSc^{1,9}

1 Department of Cardiology, Herlev-Gentofte Hospital University of Copenhagen, Denmark

2 The National Institute of Public Health, University of Southern Denmark and The Danish Heart Foundation

3 Department of Nephrology, University Hospital Copenhagen Rigshospitalet, Denmark

4 Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark

5 Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark

6 The Heart Centre, University Hospital Copenhagen Rigshospitalet, Denmark

7 Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark

8 Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark

9 Clinical Institute, Aalborg University, Aalborg, Denmark.

10 Division of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America

11 Department of Cardiology and Clinical Epidemiology, Aalborg University Hospital and Department of Health Science and Technology, Aalborg University, Aalborg, Denmark

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/hdi.12728](https://doi.org/10.1111/hdi.12728)

Address for correspondence:

Mavish Safdar Chaudry, MD,

Department of Cardiology, Gentofte Hospital, Post 635

Niels Andersens Vej 65, 2900 Hellerup, Denmark

E-mail: mavish89@hotmail.com

Phone: (+45)28112786 FAX: (+45)70201281

Conflict of Interest Statement: VF received grants from NIH, MedImmune,

Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis,

Cubist/Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius and Centers for Disease

Control; personal fees from Merck, Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm,

Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetrphase, Trius, MedImmune, Byer,

Theravance, Cubist, Basilea, Affinergy, Jenssen, Contrafect, xBiotech, Green Cross, Cubist, and

UpToDate; pending patent: Sepsis Diagnostics, outside this work.

Funding: None.

Abstract

Introduction *Staphylococcus aureus* bacteremia (SAB) is a high-risk infection and feared complication related to hemodialysis. This study aimed to investigate incidence and risk factors for SAB depending on hemodialysis access type.

Methods The Danish National Registry on Regular Dialysis and Transplantation was used to identify patients from January 1, 1996 to December 31, 2011 with end-stage kidney disease. Information on SAB was obtained from the national SAB Database. Patients were followed until death, the first episode of SAB, or end of study (December 31, 2011). Independent risk factors were assessed by multivariable Poisson regression with time-updated exposure variables.

Findings 9997 patients were included. The initial modality of renal replacement therapy was hemodialysis in 6826 patients and peritoneal dialysis in 2882 patients; 289 patients had pre-emptive kidney transplantation. SAB occurred in 1278 patients (12.8%). The incidence rate of SAB declined after 90 days and leveled off after 270 days in hemodialysis, peritoneal dialysis and kidney transplanted. As compared to peritoneal dialysis, the adjusted rate ratio (RR) for SAB was 7.42 (95% CI 5.63-9.79) in uncuffed central venous catheter (CVC), 5.68 (95% CI 4.39-7.36) in cuffed CVC, 4.43 (95% CI 2.10-9.53) in arteriovenous graft and 3.40 (95% CI 2.79-4.15) in arteriovenous fistula. SAB risk did not differ between uncuffed- and cuffed CVC. The risk of SAB was increased during the first three months of renal replacement therapy especially for CVC (RR 11.37 (95% CI 7.09-18.22)) compared with peritoneal dialysis. Diabetes mellitus (RR 1.35 (95% CI 1.20-1.51)) and male sex (RR 1.15 (95% CI 1.03-1.29)) were also associated with SAB.

Discussion Patients on hemodialysis had a high incidence rate of SAB, particularly those undergoing hemodialysis via CVC. SAB risk was comparable for cuffed- and uncuffed CVC. Diabetes mellitus, male sex, and the first three months in renal replacement therapy in particular CVC were independently associated with SAB.

Keywords

Staphylococcus aureus bacteremia, hemodialysis access type, renal replacement therapy

Background

Staphylococcus aureus bacteremia (SAB) is a serious, common complication of hemodialysis (1-17). Several characteristics contribute to the increased risk of SAB among hemodialysis patients, including the need for repeated invasive procedures, disruption of the skin barrier, and compromised immune system related to uremia (10;18).

Although different forms of hemodialysis intravascular access are known to confer different risks of SAB (15;19), the incidence rate and risk factors for SAB according to the type of hemodialysis vascular access is not well studied.

The aim of this study was 1) to estimate the incidence of SAB according to form of vascular access (uncuffed-, cuffed central venous catheter (CVC), arteriovenous graft and arteriovenous fistula) and 2) to identify risk factors for SAB among hemodialysis dependent patients.

Materials and Methods

Data sources

In Denmark, every resident is provided a permanent identification number at birth or immigration, allowing linkage between nationwide administrative registries at an individual level. In the present study, five of these nationwide registries were assessed. The Danish National Patient Registry was established in 1978 and includes information on diagnoses and procedural codes. Each outpatient appointment and hospital admission is coded at discharge with one primary diagnosis, and if appropriate, one or more secondary diagnoses, all according to the 8th revision of the International Classification of Diseases, and since 1994 the 10th revision (20). The diagnosis codes used to obtain information on comorbidity are considered valid (21). The National Civil Registry contains

information on every death occurring in Denmark. The Danish National Prescription Registry contains information on every dispensed prescription since 1995, including date of purchase, coded according to the Anatomical Therapeutic Classification in Denmark. This registry is considered accurate and valid (22). The Danish National Registry on Regular Dialysis and Transplantation was established in 1990 and holds information on all Danish patients in renal replacement therapy including changes in therapy for end-stage kidney disease and is considered valid (23). The nationwide SAB Database was established in 1956 at Statens Serum Institut. This database registers more than 94% of *staphylococcus aureus* positive blood cultures in Denmark, referred from Departments of Clinical Microbiology all over Denmark (24).

Population

The study population comprised all end-stage kidney disease patients initiating renal replacement therapy in the period from January 1, 1996 to December 31, 2011 assessed via The Danish National Registry on Regular Dialysis and Transplantation. Renal replacement therapy included hemodialysis, peritoneal dialysis, and kidney transplantation (transplantation carried out pre-emptively and after initiation of either hemodialysis or peritoneal dialysis).

End-stage kidney disease patients initiating or changing renal replacement treatment to either peritoneal dialysis or kidney transplantation from hemodialysis were included in the study to allow treatment switch and complete analyses of time spent in hemodialysis during follow-up. Hence, every change in renal replacement therapy modality was identified and entered time-updated, allowing each patient to change renal replacement therapy subgroup (e.g. from hemodialysis to

kidney transplantation, adding risk time to more than one subgroup) during follow-up. For classification of dialysis modality and hemodialysis vascular access type, detailed information including CVC (cuffed and uncuffed), arteriovenous fistula, arteriovenous graft and peritoneal catheter were obtained from The Danish National Patient Registry and combined with primary and changing treatment modalities of hemodialysis, peritoneal dialysis and kidney transplantation from The Danish National Registry on Regular Dialysis. Hemodialysis patients with a failed- or an immature arteriovenous fistula added risk time to a cuffed- or an uncuffed central venous catheter until the arteriovenous fistula was available for hemodialysis. The data were accessed at individual level in collaboration with two independent nephrologists.

Comorbidities

Data on comorbidities were retrieved from The Danish National Patient Registry up to five years before initiation of renal replacement therapy until event, death or study end. The diagnosis of diabetes mellitus was derived from redemption of antidiabetic drugs from The Danish National Prescription Registry.

Outcome

The outcome of interest was the first event of SAB after initiation of renal replacement therapy in the period 1996-2011 and was derived from the nationwide SAB Database. All patients were followed until event, death or study end (December 31, 2011).

Ethics

The present observational registry-based study was approved by the Danish Data Protection Agency (ref. 2007-58-0015 / internal ref. GEH-2014-015 I-suite no. 02733).

Statistical analyses

Continuous data are presented as mean±standard deviation. Differences between categorical variables were analysed with Chi-squared test. Differences between continuous variables were analysed with non-parametric tests. The incidence of SAB was based on the number of events in the study population divided by the time interval spent in each modality of renal replacement therapy. Multivariable Poisson regression was used to determine the association of SAB with each renal replacement therapy modality (hemodialysis, CVC (cuffed and uncuffed), arteriovenous fistula, arteriovenous graft, peritoneal dialysis and kidney transplantation) and to identify independent risk factors for SAB. The model included renal replacement therapy modality time-dependently, allowing each patient to change modality during follow-up (e.g. from hemodialysis to kidney transplantation, adding risk time to more than one subgroup). Sex, age and comorbidities (diabetes mellitus, mitral- and aortic valve disease) were covariates in the models. Comorbidities were entered time-dependently at the time each was noted. Diabetes mellitus was noted at the time glucose-lowering prescription was purchased. The current calendar year was split and entered into the model in bands of five years, and age was included in the model in bands of one year. The model was adjusted for the overall time spent in renal replacement therapy, which was split into time bands of three periods of 90 days, 270 days, and >270 days until event, death or study end. The second period was selected to represent the second quartile distribution of outcome. Poisson trend test was performed to test for significant change in the incidence of SAB across the study period.

Interaction between the modalities of renal replacement therapy and sex, age, calendar year, diabetes mellitus, mitral- and aortic valve disease was tested and found to be non-significant except for the overall time spent in each period of renal replacement therapy. Stratified analysis of overall time spent in each period of renal replacement therapy was performed to assess this interaction. Statistical analyses were performed using SAS version 9.4 (SAS institute, Cary, NC, USA), and $p < 0.05$ was considered significant.

Results

Characteristics of the study population

A total of 9997 patients initiated renal replacement therapy from January 1, 1996 to December 31, 2011. At baseline, 6826 patients initiated renal replacement therapy by hemodialysis, 2882 by peritoneal dialysis, and 289 were pre-emptive kidney transplanted, Table 1 (Supplemental Tables 1 and 2).

Incidence of SAB

A total of 1278 initial episodes of SAB were identified during the study period in the entire cohort of 9997 renal replacement recipients. Hemodialysis accounted for 1119 of the SAB events, peritoneal dialysis for 117 and kidney transplanted for 42. SAB reoccurred twice in 40 patients and three times in four patients. Recurrence of SAB was defined as at least 90 days apart the previous SAB event. The incidence rate of SAB remained constant during the last decade of the study period, Figure 1.

The overall incidence rate of SAB was 19.3/100 person-years in the first 90 days in renal replacement therapy, Figure 2. The incidence rate was significantly higher in hemodialysis (27.4/100 person-years) than in peritoneal dialysis (3.3/100 person-years) and kidney transplant recipients (7.8/100 person-years). The incidence rate was 36.5/100 person-years in the unknown hemodialysis access subset, representing unclassified hemodialysis vascular accesses with unavailable information for further categorization.

The incidence rate of SAB in the first 90 days in hemodialysis patients with uncuffed CVC was 42.6/100 person-years, in cuffed CVC 24/100 person-years, in arteriovenous fistula 23.6/100 person-years and in arteriovenous graft 19.3/100 person-years.

The incidence rate of SAB continued to decrease after 90- and 270 days in every modality of renal replacement therapy.

During the first year in renal replacement therapy, 48.7% of the total number of SAB events occurred in the hemodialysis patients, 4.6% in peritoneal dialysis, and 1.1% in kidney transplanted patients.

At the time of SAB, the hemodialysis vascular access was an arteriovenous fistula in 50.8% of patients, cuffed CVC in 10%, uncuffed CVC in 7.3%, arteriovenous graft in 0.5% and unclassified in 19%.

Factors associated with SAB

Figure 3 shows the results of the adjusted multivariable Poisson regression for the first episode of SAB in the various modalities of renal replacement therapy. The rate ratio (RR) of SAB was 4.10

(95% CI 3.39-4.97) in hemodialysis patients, 0.38 (95% CI 0.27-0.55) in kidney transplanted patients, 4.43 (95% CI 2.10-9.53) in arteriovenous graft, 3.40 (95% CI 2.79-4.15) in arteriovenous fistula, 5.68 (95% CI 4.39-7.36) in cuffed CVC, and 7.42 (95% CI 5.63-9.79) in uncuffed CVC compared with peritoneal dialysis. The risk of SAB did not differ between uncuffed CVC and cuffed CVC (RR 1.29 95% CI 0.99-1.69). In the first three months of renal replacement therapy, the risk of SAB was 5.96 (95% CI 5.25-6.76) and 1.67 (95% CI 1.42-1.96) for 91-270 days compared to >270 days in renal replacement therapy. Diabetes mellitus and male sex were independently associated with SAB with RRs of 1.35 (95% CI 1.20-1.51) and 1.15 (95% CI 1.03-1.29), respectively. The relation between aortic valve disease (RR 1.07 95% CI 0.82-1.38) or mitral valve disease (RR 1.27 95% CI 0.94-1.70) and SAB did not reach statistical significance.

In the first three months in renal replacement therapy, the risk of SAB was 11.37 (95% CI 7.09-18.22) in CVC, 7.22 (95% CI 4.49-11.10) in arteriovenous fistula, and 2.07 (95% CI 0.84-5.08) in kidney transplanted patients compared to peritoneal dialysis, Figure 4.

Ninety-day mortality was 5.6%, whereas the mortality rate in the subsequent period (91-270 days) was 9.2% in the end-stage kidney disease patients.

Discussion

In this nationwide study of end-stage kidney disease patients, the incidence rate of SAB was 4-fold higher in hemodialysis patients regardless of vascular access as compared with peritoneal dialysis. For hemodialysis patients, vascular access type was important. Patients with a CVC had a higher incidence rate of SAB than those with arteriovenous fistula as dialysis access. Of note, risk for SAB

did not differ between uncuffed- and cuffed CVC. In addition, the risk was significantly increased during the first three months of renal replacement therapy compared to >270 days. The first three months in renal replacement therapy constituted a higher risk for SAB in CVC than arteriovenous fistula, with both compared to peritoneal dialysis.

The overall incidence rate of SAB in this end-stage kidney disease study population was considerably higher than in the general Danish population (0.026/100 person-years) (24). This difference might be explained by impaired immune defense related to uremia and repeated access to the vascular system and peritoneum, along with immunosuppressive therapy increasing susceptibility to bacteremia in the end-stage kidney disease population (10;25;26).

In a retrospective case series of 898 patients, Wang et al analysed 366 hemodialysis- and 532 peritoneal dialysis patients with 191 episodes of bacteremia during 2003-2008 at a single hospital (27). Similar to our current data, they found a higher incidence rate of bacteremia in hemodialysis than in peritoneal dialysis. However, patients were censored at switch in treatment modality, at transplantation and at change in dialysis affiliation.

Recently, a Danish study by Nielsen et al reported the overall distribution of SAB incidence rates in end-stage kidney disease patients, with hemodialysis at the high end and kidney transplanted patients at the low end (28). This pattern might be explained by repeated vascular access and the local granulocyte defect at the access site in hemodialysis patients (29), which seems to exceed the risk of bacteremia related to immunosuppressive therapy in kidney transplanted patients. Moreover, Nielsen et al reported a higher overall incidence rate of SAB in patients on peritoneal dialysis than kidney transplant patients. We investigated the SAB incidence rate during three time periods of

renal replacement therapy and found an initial higher SAB rate in kidney transplanted than in peritoneal dialysis patients, which decreased below the rate of peritoneal dialysis after 270 days.

In a recent large retrospective study of US hemodialysis patients, Nguyen et al analysed the incidence rate of overall bacteremia and reported the highest rate in CVCs followed by arteriovenous graft and arteriovenous fistula (30). Arteriovenous graft is applied to a limited extent in Denmark, which leaves the rate inconclusive. However, the CVCs remain the main contributor to high rates of SAB in hemodialysis patients. Taken together, these results emphasize the importance of initiating renal replacement therapy with the establishment of an arteriovenous fistula, reducing the time of CVC access in an effort to decrease SAB events.

Previous studies have addressed the risk of infections in CVC with incongruent results. Two population studies by Stevenson et al (31) and Tokars et al (32) suggested a possible lower risk of infection in cuffed- versus uncuffed CVC. In contrast, Taylor et al (15) found no difference between them. Taylor et al included 527 hemodialysis patients and identified 93 first time bacteremia events from nine hemodialysis units, enrolled from 1998-1999 with a follow-up of 6 months for each patient. Taylor et al censored the patients at switch in treatment modality and at change in dialysis unit. The current results are comparable to the findings of Taylor et al, but our cohort of end-stage kidney disease patients was national, patients were followed up to a maximum of 16 years, were allowed to stay in the study at switch in treatment modality and remained in the study at change in dialysis affiliation.

The mortality rate in hemodialysis patients was remarkably high in the initial period after commencement of hemodialysis. Robinson et al (33) reported mortality rates in patients initiating

hemodialysis of 26.7/100 patient-years in the first 120 days, decreasing to 16.9/100 patient-years and 13.7/100 patient-years at 121-365 days and >365 days, respectively. We found a high mortality in end-stage kidney disease patients after initiation of renal replacement therapy within the first nine months. In a large cohort including 86,886 patients initiating hemodialysis from 11 countries, Jager et al found cardiovascular death as the leading cause of death followed by infections (34). The patients were included from the ERA-EDTA registry during 1994-2007, with a mean follow-up of 1.8 years. We demonstrated a high risk of SAB in CVC and arteriovenous fistula during the initial 90 days of renal replacement therapy, which declined after 90 days and levelled off after 270 days. These results might be explained by the initial high mortality from cardiovascular causes and infections, resulting in a continuous selection for less comorbid patients throughout the initial period of hemodialysis.

Diabetes mellitus and male sex constituted an independent risk factor for SAB in accordance with previous literature (10;35;36).

Strengths and limitations

The study is limited to the observational design. The events in the unknown hemodialysis vascular access subset are most likely a combination of cuffed- and uncuffed CVCs, since arteriovenous graft and arteriovenous fistula require surgical intervention, misclassification is less likely. In addition, the codes denoting the hemodialysis access are not formally validated, thus misclassification concerning the differentiation between cuffed- and uncuffed CVC cannot be excluded even though the procedural codes in the registry were reviewed manually for each individual patient. It should be noted that the cohort of end-stage kidney disease patients is large

and nationwide, including every patient initiating renal replacement therapy in the study period. Moreover, every change in treatment modality during the study period was tracked at the individual level.

Conclusion

In a nationwide end-stage kidney disease population, the incidence rate of SAB declined after 90 days and leveled off after 270 days in hemodialysis, peritoneal dialysis and kidney transplanted. The incidence rate of SAB in CVCs was higher than in arteriovenous fistula. SAB risk did not differ between cuffed- and uncuffed CVC. Diabetes mellitus, male sex and the first three months in renal replacement therapy especially in CVC were independent risk factors for SAB. These results emphasize the importance of arteriovenous fistula as the primary vascular access in hemodialysis and strongly suggest limited use of CVCs.

Abbreviations

SAB: Staphylococcus aureus bacteremia, **CVC:** central venous catheter, **RR:** Rate ratio

Acknowledgements: None.

Reference List

- (1) Abbott KC, Agodoa LY. Etiology of bacterial septicemia in chronic dialysis patients in the United States. *Clin Nephrol* 2001 Aug;56(2):124-31.
- (2) Al-Solaiman Y, Estrada E, Allon M. The spectrum of infections in catheter-dependent hemodialysis patients. *Clin J Am Soc Nephrol* 2011 Sep;6(9):2247-52.
- (3) Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, et al. Clinical outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term hemodialysis. *Infect Control Hosp Epidemiol* 2005 Jun;26(6):534-9.
- (4) Fitzgerald SF, O'Gorman J, Morris-Downes MM, Crowley RK, Donlon S, Bajwa R, et al. A 12-year review of *Staphylococcus aureus* bloodstream infections in haemodialysis patients: more work to be done. *J Hosp Infect* 2011 Nov;79(3):218-21.
- (5) Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998 May;9(5):869-76.
- (6) Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with *Staphylococcus aureus* bacteremia. *Clin J Am Soc Nephrol* 2006 May;1(3):518-24.

- (7) Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. *Kidney Int* 2005 Jul;68(1):311-8.
- (8) Nielsen J, Kolmos HJ, Espersen F. Staphylococcus aureus bacteraemia among patients undergoing dialysis--focus on dialysis catheter-related cases. *Nephrol Dial Transplant* 1998 Jan;13(1):139-45.
- (9) Peacock SJ, Curtis N, Berendt AR, Bowler IC, Winearls CG, Maxwell P. Outcome following haemodialysis catheter-related Staphylococcus aureus bacteraemia. *J Hosp Infect* 1999 Mar;41(3):223-8.
- (10) Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. *Kidney Int* 1999 Mar;55(3):1081-90.
- (11) Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. *Am J Kidney Dis* 1999 Dec;34(6):1114-24.
- (12) Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. *Infect Dis Clin North Am* 2001 Sep;15(3):731-42, vii.
- (13) Stefan G, Stancu S, Capusa C, Ailioaie OR, Mircescu G. Catheter-related infections in chronic hemodialysis: a clinical and economic perspective. *Int Urol Nephrol* 2013 Jun;45(3):817-23.

- (14) Sullivan R, Samuel V, Le C, Khan M, Alexandraki I, Cuhaci B, et al. Hemodialysis vascular catheter-related bacteremia. *Am J Med Sci* 2007 Dec;334(6):458-65.
- (15) Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. *Am J Infect Control* 2004 May;32(3):155-60.
- (16) Taylor GD, McKenzie M, Buchanan-Chell M, Caballo L, Chui L, Kowalewska-Grochowska K. Central venous catheters as a source of hemodialysis-related bacteremia. *Infect Control Hosp Epidemiol* 1998 Sep;19(9):643-6.
- (17) Troidle L, Eisen T, Pacelli L, Finkelstein F. Complications associated with the development of bacteremia with *Staphylococcus aureus*. *Hemodial Int* 2007 Jan;11(1):72-5.
- (18) Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense. *Nephron* 1993;63(2):125-31.
- (19) Dopirak M, Hill C, Oleksiw M, Dumigan D, Arvai J, English E, et al. Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers. *Infect Control Hosp Epidemiol* 2002 Dec;23(12):721-4.
- (20) Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Health* 2011 Jul;39(7 Suppl):30-3.
- (21) Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the

population-based Danish National Registry of Patients. BMC Med Res Methodol 2011;11:83.

- (22) Rasmussen L, Valentin J, Gesser KM, Hallas J, Pottegard A. Validity of the Prescriber Information in the Danish National Prescription Registry. Basic Clin Pharmacol Toxicol 2016 Apr 21.
- (23) Hommel K, Rasmussen S, Madsen M, Kamper AL. The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant 2010 Mar;25(3):947-51.
- (24) Statens Serum Institut Staphylococcus aureus bacteraemia Cases in Denmark 2015 [cited 2017 Oct 1]; Available from: URL: <https://www.ssi.dk/~media/Indhold/DK%20-%20dansk/Smitteberedskab/Referencelaboratorier/Stafylokoklaboratoriet/SAB%202015%20final.ashx>
- (25) O'Seaghda CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005 Nov;25(6):534-40.
- (26) Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C, et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant 2015 Jun;30(6):1028-37.

- (27) Wang IK, Chang YC, Liang CC, Chuang FR, Chang CT, Lin HH, et al. Bacteremia in hemodialysis and peritoneal dialysis patients. *Intern Med* 2012;51(9):1015-21.
- (28) Nielsen LH, Jensen-Fangel S, Benfield T, Skov R, Jespersen B, Larsen AR, et al. Risk and prognosis of *Staphylococcus aureus* bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study. *BMC Infect Dis* 2015 Jan 8;15:6.
- (29) Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. *J Clin Invest* 1984 Apr;73(4):1191-200.
- (30) Nguyen DB, Shugart A, Lines C, Shah AB, Edwards J, Pollock D, et al. National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. *Clin J Am Soc Nephrol* 2017 Jul 7;12(7):1139-46.
- (31) Stevenson KB, Hannah EL, Lowder CA, Adcox MJ, Davidson RL, Mallea MC, et al. Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. *Am J Kidney Dis* 2002 Mar;39(3):549-55.
- (32) Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial results. *Am J Infect Control* 2002 Aug;30(5):288-95.

- (33) Robinson BM, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int* 2014 Jan;85(1):158-65.
- (34) de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. *JAMA* 2009 Oct 28;302(16):1782-9.
- (35) Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive *Staphylococcus aureus* infections. *J Infect Dis* 2003 May 1;187(9):1452-9.
- (36) Lemaire X, Morena M, Leray-Moragues H, Henriët-Viprey D, Chenine L, Defez-Fougeron C, et al. Analysis of risk factors for catheter-related bacteremia in 2000 permanent dual catheters for hemodialysis. *Blood Purif* 2009;28(1):21-8.

Figure Legends

Figure 1. Incidence rate of SAB in renal replacement therapy recipients

Figure 2. The incidence rate of SAB in various renal replacement therapy modalities

*134.6/100 person-years

HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation; T, total; AV-F, arteriovenous fistula; AV-G, arteriovenous graft; C-CVC, cuffed central venous catheter; U-CVC,

uncuffed central venous catheter; Un-HD, unknown hemodialysis; 95% CI, 95% confidence interval

Figure 3. Risk factors for SAB in patients receiving renal replacement therapy

*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease, calendar time, renal replacement therapy periods (≤ 90 days-, 91-270 days- or >270 days in renal replacement therapy).

†Renal replacement therapy period 1: first 90 days in renal replacement therapy, renal replacement therapy period 2: 91-270 days in renal replacement therapy, renal replacement therapy period 3: >270 days in renal replacement therapy to event, death, or study end.

‡ CVC, central venous catheter, RR, Rate ratio, 95% CI, 95% confidence interval

Figure 4. Risk of SAB in renal replacement therapy according to time in renal replacement therapy

*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease, and calendar time

95% CI, 95% confidence interval